Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: Pooled 48 week analysis of two randomized, controlled trials

AIDS

Volumn 23, Issue 17, 2009, Pages 2289-2300

  Katlama, Christine ^a   Haubrich, Richard ^b   Lalezari, Jacob ^c   Lazzarin, Adriano ^d   Madruga, José V ^e   Molina, Jean Michel ^f   Schechter, Mauro ^g   Peeters, Monika ^h   Picchio, Gaston ⁱ   Vingerhoets, Johan ^h   Woodfall, Brian ^h   De Smedt, Goedele ^h  

^a SORBONNE UNIVERSITÉ   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Quest Clinical Research   (United States)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e Centro de Referencia e Treinamento DST/AIDS   (Brazil)

^f SAINT LOUIS HOSPITAL   (France)

^g FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^h TIBOTEC BVBA   (Belgium)

ⁱ Tibotec Inc   (United States)

Author keywords

Antiretroviral agents; DUET; Etravirine; HIV; Nonnucleoside reverse transcriptase inhibitor; TMC125

Indexed keywords

DARUNAVIR PLUS RITONAVIR; ENFUVIRTIDE; ETRAVIRINE; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENE MUTATION; GENOTYPE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INJECTION SITE REACTION; INSOMNIA; KIDNEY FAILURE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NAUSEA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD; VIRUS RESISTANCE; VOMITING;

ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DOUBLE-BLIND METHOD; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 70449368908     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283316a5e     Document Type: Article

References (31)

1. Antinori A, Zaccarelli M, Cingolani A, Forbici F, Rizzo MG, Trotta MP, et al. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses 2002; 18:835-838.
2. Delaugerre C, Rohban R, Simon A, Mouroux M, Tricot C, Agher R, et al. Resistance profile and cross-resistance of HIV-1 among patients failing a nonnucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol 2001; 65:445-448
3. US Department of Health and Human Services (DHHS). Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents pp. 1-128. http://aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGL.pdf. [Accessed 19 February 2008].
4. Perez-Molina JA. Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clin Trials 2002; 3:279-286.
5. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363:1253-1263.
6. Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005; 191:825-829.
7. Bristol-Myers Squibb. Sustiva (efavirenz) US prescribing information. http://packageinserts.bms.com/pi/pi-sustiva.pdf. [Accessed 5 May 2009].
8. Boehringer Ingelheim Pharmaceuticals, Inc. Viramune (nevira-pine) US prescribing information. http://us.viramune.com. [Accessed 5 May 2009].
9. Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48:4680-4686.
10. Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:29-38.
11. Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:39-48.
12. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: fall 2005. Top HIV Med 2005; 13:125-131.
13. Emery S, Abrams DI, Cooper DA, Darbyshire JH, Lane HC, Lundgren JD, et al. The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials 2002; 23: 198-220.
14. Vingerhoets J, Peeters M, Azijn H, Tambuyzer L, Hoogstoel A, Nijs S, et al. An update of the list of NNRTI mutations associated with decreased virological response to etravirine: multi-variate analyses on the pooled DUET-1 and DUET-2 clinical trial data. Antivir Ther 2008; 13:A26.
15. Peeters M, Nijs S, Vingerhoets J, Tambuyzer L, Woodfall B, de Béthune M-P, et al. Determination of phenotypic clinical cutoffs for etravirine: pooled Week 24 results of the DUET-1 and DUET-2 trials. Antivir Ther 2008; 13:A133.
16. Johnson VA, Brun-Vézinet F, Clotet B, Günthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007; 15:119-125.
17. Hammer SM, Saag M, Schechter M, Montaner J, Schooley RT, Jacobsen DM, et al. Treatment for adult HIV infection. 2006 recommendations of the International AIDS Society-USA Panel. JAMA 2006; 296:827-843.
18. Clumeck N, Pozniak A, Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008; 9:65-71.
19. Gazzard B, Bernard AJ, Boffito M, Churchill D, Edwards S, Fisher N, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006; 7:487-503.
20. Youle M, Cohen C, Katlama C, Kuritzkes D, Walmsley S. Codevelopment of new antiretrovirals in very treatment-experienced HIV-infected individuals. Lancet 2004; 364: 1036-1037.
21. Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169-1178.
22. Hirschel B, Perneger T. No patient left behind: better treatments for resistant HIV infection. Lancet 2007; 370:3-5.
23. Vingerhoets J, Azijn H, Fransen E, De Baere I, Smeulders L, Jochmans D, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 2005; 79:12773-12782.
24. Cahn P, Haubrich R, Leider J, Pialoux G, Schechter M, Walms-ley S, et al. Pooled 24-week results of DUET-1 and DUET-2: TMC125 (etravirine; ETR) versus placebo in 1203 treatment-experienced HIV-1-infected patients [abstract H-717]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, USA, 2007.
25. World Health Organization. Initiative on HIV/AIDS and sexually transmitted infections. Use of antiretroviral treatments in adults with particular references to resource limited settings. http://whqlibdoc.who.int/hq/ 2000/WHO-HSI-2000.04.pdf. [Accessed 10 March 2008].
26. Schöller M, KraftM, Hoetelmans R, Vyncke V, Vandermeulen K, Peeters M, et al. Significant decrease in TMC125 exposures whenco-administered withtipranavir (boosted with ritonavir) in healthysubjects[abstract583]. 13th Conference on Retroviruses and Opportunistic Infections, Denver, Colorado, USA, 2007.
27. Davis J, Schöller-Gyüre M, Kakuda TN, Ridgway C, Tweedy S, Ndongo N, et al. An open, randomized, two-period, crossover study in two cohorts to investigate the effect of steady-state TMC125 (etravirine) and the combination of TMC125/daru-navir/ritonavir on the steady-state pharmacokinetics of oral maraviroc in healthy subjects [abstract P4.3/02]. 11th European AIDS Conference, Madrid, Spain, 2007.
28. Anderson MS, Kakuda TN, Miller JL, Simonts M, Miller D, Hanley W, et al. Pharmacokinetic evaluation of nonnucleoside reverse transcriptase inhibitor (NNRTI) TMC125 and integrase inhibitor (InSTI) raltegravir (RAL) in healthy subjects [abstract TUPDB02]. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, 2007.
29. Fagard C, Descamps D, Dunbar V, Colin C, Taburet A-M, Roquebert B, et al. Efficacy and safety of raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: 48-week results from the ANRS 139 TRIO trial [abstract TUPDB204]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa; 2009.
30. Flys TS, Donnell D, Mwatha A, Nakabiito C, Musoke P, Mmiro F, et al. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis 2007; 195:711-715.
31. Dykes C, Demeter LM. Clinical significance of human immunodeficiency virus type 1 replication fitness. Clin Microbiol Rev 2007; 20:550-578